Business description: Sanofi

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:

- pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases);

- human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.

At the end of 2024, the group had 52 production sites worldwide.

In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation.

Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Number of employees: 82,878

Sales by Activity: Sanofi

Fiscal Period: December20202021202220232024

Biopharma

- - - 41.21B 43.95B

Consumer Healthcare

4.45B 4.52B 5.14B 5.23B -

Pharmaceuticals Excl. Consumer Healthcare

25.8B 27.23B 31.34B - -

Vaccines

7.11B 7.42B 8.9B - -

Others

- - 7M - 339M
See all business segments

Geographical breakdown of sales: Sanofi

Fiscal Period: December20202021202220232024

United States

13.46B 14.38B 18.28B 18.51B 19.99B

Rest of The World

7.76B 7.85B 8.39B 13.46B 12.07B

Europe (Excluding France)

- - - 8.01B 7.21B

France

- - - 2.38B 1.81B

Europe (Excl. Russia)

9.15B 9.76B 10B - -

China

2.45B 2.72B 3.12B - -

Russia

641M 575M 674M - -

Brazil

836M 815M 927M - -

North America (Excluding United States)

- - - 704M -

Japan

1.74B 1.66B 1.61B - -
See all geographic segments

Executive Committee: Sanofi

Manager TitleAgeSince
Chief Executive Officer 57 2019-08-31
Director of Finance/CFO 63 2024-03-31
Chief Operating Officer 41 2023-09-30
Chief Tech/Sci/R&D Officer 50 2023-09-10
Investor Relations Contact 51 -
See SANOFI governance

Composition of the Board of Directors: Sanofi

Director TitleAgeSince
Director/Board Member 62 2013-05-02
Director/Board Member 71 2014-04-30
Director/Board Member 59 2019-04-29
Director/Board Member 57 2019-10-29
Director/Board Member 55 2020-04-27
Director/Board Member 63 2020-04-27
Director/Board Member 57 2021-04-29
Director/Board Member 59 2021-04-30
Director/Board Member 57 2021-03-31
Director/Board Member 54 2022-05-02
Composition of the Board of Directors

Shareholders: Sanofi

NameEquities%Valuation
7.188 %
88,670,657 7.188 % 8 557 M €
Dodge & Cox
1.825 %
22,512,304 1.825 % 2 172 M €
1.317 %
16,245,648 1.317 % 1 568 M €
Amundi Asset Management SASU (Investment Management)
0.4503 %
5,554,878 0.4503 % 536 M €
OFI Invest Asset Management SA
0.3048 %
3,760,272 0.3048 % 363 M €
NameEquities%Valuation
Dodge & Cox
2.897 %
73,193,057 2.897 % 3 536 M €
Fisher Asset Management LLC
0.537 %
13,566,329 0.537 % 655 M €
Invesco Advisers, Inc.
0.4695 %
11,859,545 0.4695 % 573 M €
T. Rowe Price International Ltd.
0.4369 %
11,036,878 0.4369 % 533 M €
Merrill Lynch International
0.412 %
10,407,790 0.412 % 503 M €
List of SANOFI shareholders

Holdings: Sanofi

NameEquities%Valuation
16,245,648 1.32% 1,567,740,935 $
13,909,587 60.4% 1,034,112,001 $
13,909,587 60.4% 923,724,128 $
28,298,074 29.6% 95,866,234 $
12,197,737 15.61% 79,529,245 $
6,880,481 4.3% 43,347,030 $
821,917 2.7% 18,246,557 $
1,157,926 8% 16,523,604 $
8,345,387 9.96% 14,909,868 $
14,571,428 6.21% 11,635,285 $

Company details: Sanofi

Sanofi

46, avenue de la Grande Armée

75017, Paris

+33 1 53 77 40 00

http://www.sanofi.com
address Sanofi(SAN)

Group companies: Sanofi

NameCategory and Sector
Pharmaceuticals: Major
Miscellaneous
Pharmaceuticals: Major
Biotechnology
Rhone-Poulenc Rorer Asia Pacific Ltd.
See all subsidiaries

Other Pharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
-0.04%+0.25%-9.62%-16.63% 119B
+0.80%+3.42%-15.72%+144.53% 718B
-0.05%+1.00%+4.63%-10.74% 377B
-0.48%+2.07%+12.47%+27.31% 338B
+0.06%-1.38%-54.41%+6.02% 308B
-0.02%-0.08%-0.46%-22.40% 259B
+0.64%-0.84%-2.23%+17.27% 237B
+0.08%+2.90%-12.10%-4.23% 222B
+0.37%+3.42%-34.51%-10.88% 210B
+0.60%+1.39%-10.22%+20.95% 160B
Average +0.12%+1.07%-12.22%+15.12% 294.89B
Weighted average by Cap. +0.03%+1.47%-12.02%+36.35%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
BBB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
83.54EUR
Average target price
112.64EUR
Spread / Average Target
+34.84%
Consensus

Quarterly revenue - Rate of surprise